New drug STM-416p tested during prostate surgery in small safety trial

NCT ID NCT06450106

Recruiting now Disease control Sponsor: SURGE Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a drug called STM-416p that is given directly during surgery to remove the prostate in men with prostate cancer. The study involves 18 men and focuses on safety and finding the right dose. It is not yet testing whether the drug works better than standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STM-416p (a drug given during surgery)
What this could lead to: If it works, this could point toward a new way to treat prostate cancer during surgery, potentially reducing the chance of cancer coming back.
What could go wrong: This is a very early Phase 1 trial with only 18 people, so the main goal is safety, not effectiveness. It may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Arizona Urology Specialists
RECRUITING

Tucson, Arizona, 85715, United States
Australian Prostate Center
RECRUITING

Melbourne N., Victoria, 3051, Australia
Epworth HealthCare
RECRUITING

Melbourne N., Victoria, 3051, Australia
University of Florida
RECRUITING

Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.